NEW YORK, Feb. 11 /PRNewswire-FirstCall/ -- VaxGen, Inc. (Pink Sheets:
WHAT: Jim Panek, CEO of VaxGen, and George Schreiner, CEO of Raven, will
provide an update on Raven's oncology
pipeline, discuss the status of the Companies' proposed merger and
plans and prospects for the new Company.
WHEN: 2:45 p.m. EST, Wednesday, February 13, 2008
HOW: To listen to a live webcast of the presentation, go to
The webcast replay will be available approximately one hour after
the live presentation.
VaxGen is a biopharmaceutical company based in South San Francisco, California. The company owns a state-of-the-art biopharmaceutical manufacturing facility with a 1,000-liter bioreactor that can be used to make cell culture or microbial biologic products. For more information, please visit the company's web site at http://www.vaxgen.com.
Raven biotechnologies, inc. is a privately held biotechnology company focused on the development of monoclonal antibody therapeutics for treating cancer. Raven's lead product candidate, RAV12, targets adenocarcinomas and is in clinical development for the treatment of gastrointestinal and other cancers. Raven, which is based in South San Francisco, California, has identified multiple candidate therapeutic MAbs for many cancer indications including lung, colon, pancreatic, prostate, breast, and ovarian cancer. Please visit http://www.ravenbio.com for more information about Raven biotechnologies inc.
Note: This press release contains "forward-looking statements" within
the meaning of the federal securities laws. These forward-looking
statements include, without limitation, statements regarding quotation of
VaxGen's common stock on the OTC Bulletin Board and the
Copyright©2008 PR Newswire.
All rights reserved